Mark J. Cantwell

1.4k total citations
23 papers, 1.2k citations indexed

About

Mark J. Cantwell is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Mark J. Cantwell has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Immunology and 6 papers in Genetics. Recurrent topics in Mark J. Cantwell's work include CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (7 papers) and Virus-based gene therapy research (6 papers). Mark J. Cantwell is often cited by papers focused on CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (7 papers) and Virus-based gene therapy research (6 papers). Mark J. Cantwell collaborates with scholars based in United States, Japan and Egypt. Mark J. Cantwell's co-authors include Thomas J. Kipps, Charles Prussak, Laura Z. Rassenti, T J Kipps, Kinshi Kato, Shweta Sharma, William G. Wierda, Januario E. Castro, Li Tang and Desheng Lu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Mark J. Cantwell

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark J. Cantwell United States	10	697	439	425	397	202	23	1.2k
Alar Aints Sweden	13	354 0.5×	257 0.6×	233 0.5×	454 1.1×	121 0.6×	23	952
Tina Goossens Germany	6	573 0.8×	387 0.9×	368 0.9×	408 1.0×	523 2.6×	7	1.2k
Karla Plevová Czechia	18	519 0.7×	451 1.0×	232 0.5×	651 1.6×	279 1.4×	48	1.3k
T J Kipps United States	16	700 1.0×	623 1.4×	314 0.7×	392 1.0×	429 2.1×	23	1.4k
Mark W. Brunvand United States	15	554 0.8×	112 0.3×	293 0.7×	375 0.9×	176 0.9×	22	1.2k
L. Kerrie United States	12	548 0.8×	236 0.5×	509 1.2×	320 0.8×	204 1.0×	26	1.1k
Harvey A. Greisman United States	14	444 0.6×	271 0.6×	889 2.1×	859 2.2×	183 0.9×	22	1.8k
Charles F. Eisenbeis United States	14	820 1.2×	134 0.3×	537 1.3×	371 0.9×	247 1.2×	20	1.3k
Erich Piovan Italy	15	327 0.5×	120 0.3×	305 0.7×	375 0.9×	147 0.7×	33	915
Massimiliano Manganini Italy	10	294 0.4×	216 0.5×	223 0.5×	186 0.5×	166 0.8×	12	651

Countries citing papers authored by Mark J. Cantwell

Since Specialization

Citations

This map shows the geographic impact of Mark J. Cantwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Cantwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Cantwell more than expected).

Fields of papers citing papers by Mark J. Cantwell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Cantwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Cantwell. The network helps show where Mark J. Cantwell may publish in the future.

Co-authorship network of co-authors of Mark J. Cantwell

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Cantwell. A scholar is included among the top collaborators of Mark J. Cantwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Cantwell. Mark J. Cantwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Whitaker, Regina S., Shonagh Russell, Justin Pollara, et al.. (2024). Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer. Neoplasia. 57. 101056–101056. 5 indexed citations

Yu, Xiaoqing, Mengyu Xie, Joseph Johnson, et al.. (2023). Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunology Research. 11(4). 466–485. 9 indexed citations

Saltos, Andreas, Georgia M. Beasley, James Ronald, et al.. (2023). A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). 2569–2569. 7 indexed citations

Saltos, Andreas, Georgia M. Beasley, James Ronald, et al.. (2023). Abstract CT103: A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity. Cancer Research. 83(8_Supplement). CT103–CT103. 3 indexed citations

Zheng, Hong, et al.. (2021). Abstract 697: Defining anti-tumor immune stimulatory mechanisms of MEM-288, a CD40 ligand and IFN-beta dual-transgene armed oncolytic adenovirus. Cancer Research. 81(13_Supplement). 697–697. 1 indexed citations

Zheng, Hong, Wenjie Dai, Scott Antonia, Mark J. Cantwell, & Amer A. Beg. (2020). Abstract 4578: Development of MEM-288, a dual-transgene armed and conditionally replication-enhanced oncolytic adenovirus with potent systemic antitumor immunity. Cancer Research. 80(16_Supplement). 4578–4578. 2 indexed citations

Singh, Manisha, Mark J. Cantwell, Zhimin Dai, et al.. (2017). Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nature Communications. 8(1). 1447–1447. 68 indexed citations

Singh, Manisha, et al.. (2015). Induction of potent systemic anti-melanoma immunity through intratumoral CD40 activation and checkpoint blockade. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations

Blajman, C., Luis Fein, Matías Chacón, et al.. (2008). Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer.. Cancer Research. 68. 207–207. 1 indexed citations

10.

Rieger, R., David C. Whitacre, Mark J. Cantwell, Charles Prussak, & Thomas J. Kipps. (2008). Chimeric form of tumor necrosis factor-α has enhanced surface expression and antitumor activity. Cancer Gene Therapy. 16(1). 53–64. 6 indexed citations

11.

Fukuda, Tetsuya, Liguang Chen, Tomoyuki Endo, et al.. (2008). Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proceedings of the National Academy of Sciences. 105(8). 3047–3052. 255 indexed citations

12.

Cantwell, Mark J., et al.. (2007). A novel emulsion formulation of docetaxel eliminates hypersensitivity reactions without impacting pharmacokinetics or antitumor activity. Molecular Cancer Therapeutics. 6. 1 indexed citations

13.

Cantwell, Mark J. & Joan M. Robbins. (2005). 5,10-methylenetetrahydrofolate/5-fluorouracil combination therapy shows enhanced antitumor activity and lower systemic toxicity with a broad range of cytotoxic drugs. Cancer Research. 65. 1206–1206. 1 indexed citations

14.

Bashey, Asad, Mark J. Cantwell, & Thomas J. Kipps. (2002). Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. British Journal of Haematology. 118(2). 506–513. 4 indexed citations

15.

Wierda, William G., et al.. (2000). CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 96(9). 2917–2924. 16 indexed citations

16.

Wierda, William G., et al.. (2000). CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 96(9). 2917–2924. 272 indexed citations

17.

Kato, Kinshi, Mark J. Cantwell, Shweta Sharma, & T J Kipps. (1998). Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.. Journal of Clinical Investigation. 101(5). 1133–1141. 198 indexed citations

18.

Cantwell, Mark J., et al.. (1997). Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis & Rheumatism. 40(9). 1644–1652. 40 indexed citations

19.

Cantwell, Mark J., et al.. (1997). Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nature Medicine. 3(9). 984–989. 165 indexed citations

20.

Cantwell, Mark J., et al.. (1997). Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. The Journal of Immunology. 159(12). 5777–5781. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact